EUVIMEDEUVIMED entdecken
Crossref

Severe and fatal COVID‐19 is characterised by increased circulating glucagon like peptide 1 and procalcitonin modulated by type 2 diabetes

Olga Bloch, Perl Kobi, Ariel Ben Shimol iD, Assaf Rotmensh, Dana Kagansky, Dana Zelnik-Yovel iD, Gilad Ben Yehudah, Dror Cantrell, Micha J Rapoport

Diabetes/Metabolism Research and Reviews · 2023

DOI: 10.1002/dmrr.3635 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2023. Verfasst von Olga Bloch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes & Autoimmunity Research Laboratory, Yitzhak Shamir Medical Center, Sackler Medical School Tel Aviv University, Zerifin, Israel. Hauptthemen laut MEDLINE: COVID-19, Diabetes Mellitus, Type 2. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Endotoxemia commonly occurs in severe and fatal COVID‐19, suggesting that concomitant bacterial stimuli may amplify the innate immune response induced by SARS‐CoV‐2. We previously demonstrated that the endogenous glucagon like peptide 1 (GLP‐1) system in conjunction with increased procalcitonin (PCT) is hyperactivated in patients with severe Gram‐negative sepsis and modulated by type 2 diabetes (T2D). We aimed to determine the association of COVID‐19 severity with endogenous GLP‐1 activation upregulated by increased specific pro‐inflammatory innate immune response in patients with and without T2D. Materials and Methods Plasma levels of total GLP‐1, IL‐6, and PCT were estimated on admission and during hospitalisation in 61 patients (17 with T2D) with non‐severe and severe COVID‐19.

Results

COVID‐19 patients demonstrated ten‐fold increase of IL‐6 levels regardless of disease severity. Increased admission GLP‐1 levels ( p = 0.03) accompanied by two‐fold increased PCT were found in severe as compared with non‐severe patients. Moreover, GLP‐1 and PCT levels were significantly increased in non‐survived as compared with survived patients at admission ( p = 0.01 and p = 0.001, respectively) and at 5 to 6 days of hospitalisation ( p = 0.05). Both non‐diabetic and T2D patients demonstrated a positive correlation between GLP‐1 and PCT response ( r = 0.33, p = 0.03, and r = 0.54, p = 0.03, respectively), but the intensity of this joint pro‐inflammatory/GLP‐1 response was modulated by T2D. In addition, hypoxaemia down‐regulated GLP‐1 response only in T2D patients with bilateral lung damage.

Conclusions

The persistent joint increase of endogenous GLP‐1 and PCT in severe and fatal COVID‐19 suggests a role of concomitant bacterial infection in disease exacerbation. Early elevation of endogenous GLP‐1 may serve as a new biomarker of COVID‐19 severity and fatal outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Diabetes Mellitus, Type 2HumansProcalcitoninSARS-CoV-2Glucagon-Like Peptide 1Interleukin-6Biomarkers

Stichwörter der Autor:innen

COVID-19 severityIL-6diabeticendogenous GLP-1 responsenondiabeticprocalcitonin

Substanzen

ProcalcitoninGlucagon-Like Peptide 1Interleukin-6Biomarkers

Autor:innen und Institutionen

  • Diabetes & Autoimmunity Research Laboratory, Yitzhak Shamir Medical Center, Sackler Medical School Tel Aviv University, Zerifin, Israel.
  • Department "C" of Internal Medicine, Yitzhak Shamir Medical Center, Sackler Medical School Tel Aviv University, Zerifin, Israel.
  • Department "A" of Internal Medicine, Yitzhak Shamir Medical Center, Sackler Medical School Tel Aviv University, Zerifin, Israel.
  • Laboratory of Microbiology, Yitzhak Shamir Medical Center, Sackler Medical School Tel Aviv University, Zerifin, Israel.

ORCID-Profile: Ariel Ben Shimol, Dana Zelnik-Yovel

Zitieren

APA

Bloch, O., Kobi, P., Ben Shimol, A., Rotmensh, A., Kagansky, D., Zelnik-Yovel, D., Yehudah, G. B., Cantrell, D., & Rapoport, M. J. (2023). Severe and fatal COVID‐19 is characterised by increased circulating glucagon like peptide 1 and procalcitonin modulated by type 2 diabetes. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.3635

Vancouver

Bloch O, Kobi P, Ben Shimol A, Rotmensh A, Kagansky D, Zelnik-Yovel D, et al. Severe and fatal COVID‐19 is characterised by increased circulating glucagon like peptide 1 and procalcitonin modulated by type 2 diabetes. Diabetes/Metabolism Research and Reviews. 2023. doi:10.1002/dmrr.3635

BibTeX
@article{Bloch2023,
  author = {Bloch, Olga and Kobi, Perl and Ben Shimol, Ariel and Rotmensh, Assaf and Kagansky, Dana and Zelnik-Yovel, Dana and Yehudah, Gilad Ben and Cantrell, Dror and Rapoport, Micha J},
  title = {Severe and fatal COVID‐19 is characterised by increased circulating glucagon like peptide 1 and procalcitonin modulated by type 2 diabetes},
  journal = {Diabetes/Metabolism Research and Reviews},
  year = {2023},
  doi = {10.1002/dmrr.3635}
}
Kostenlos starten →